Once-daily dosing of lopinavir/ritonavir (Kaletra) receives FDA approval.
D019380:Anti-HIV Agents / Q000008:administration & dosage*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015658:HIV Infections / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000008:administration & dosage*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D061466:Lopinavir; D011744:Pyrimidinones / Q000008:administration & dosage*; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir